Valproate

The selected oral products treat complex partial seizures as monotherapy/adjunct therapy and simple/complex absence seizures as sole/adjunct therapy; mixed seizure types including absence may use adjunct therapy. Complex-partial label dosing specifies adults and children age ≥10. Selected IV valproate is an alternative when oral administration is temporarily infeasible, not a label-based general emergency loading protocol.

Depakote DR and ER tablets label adult manic episodes associated with bipolar disorder and adult migraine prevention. Migraine use is preventive, not acute. Their controlled antimanic evidence is short-term and long-term usefulness requires reevaluation. Sprinkle, selected valproic-acid capsules/solution and IV labels do not establish the same mania/migraine approvals; do not infer them from shared active valproate.

For complex partial seizures in adults/age ≥10, start 10–15 mg/kg/day, increasing by 5–10 mg/kg/day at weekly intervals by response. Absence starts 15 mg/kg/day with the same weekly increment. Maximum recommended 60 mg/kg/day; higher dosing lacks established label safety. Immediate-release/DR/sprinkle and IV daily doses >250 mg use divided dosing; ER is once daily. A usual total epilepsy reference range is 50–100 mcg/mL, but response/free fraction govern interpretation. Do not abruptly withdraw antiseizure therapy.

Titrate by response, tolerability and the relevant measured trough concentration. Do not transplant these regimens to unapproved formulations or children.

For adults and children ≥10 with epilepsy switching Depakote DR to ER, label conversion uses an ER daily dose 8–20% higher, with its exact available-strength table. The label lacks a conversion-factor recommendation above DR 3,125 mg/day. Verify response and levels after switching; this rule is not a universal conversion for all indications/routes. ER and DR cannot be interchanged at equal milligrams without a prescribed plan.

Swallow DR/ER tablets whole; do not crush/chew. Valproic-acid soft capsules are swallowed whole to avoid oral irritation. Depakote Sprinkle may be swallowed whole or opened onto a teaspoon of soft food; swallow immediately without chewing and do not store the mixture. Measure the selected oral solution at 250 mg/5 mL using a calibrated oral device. Food or gradual titration may reduce GI irritation.

The IV label uses the same total daily equivalent dose and frequency as oral replacement, infused over 60 minutes at ≤20 mg/min. Evidence of steady-state equivalence was assessed every six hours; less-frequent administration can need close trough monitoring. Switch back to oral as soon as feasible; >14 days IV use is unstudied. Dilute in at least 50 mL of compatible 5% dextrose, 0.9% saline or lactated Ringer’s, follow sterile technique and inspect. Faster infusion safety observations do not establish a replacement or status-epilepticus efficacy protocol.

Reduce the older-adult starting dose, titrate more slowly and monitor intake, dehydration and somnolence. Liver disease/significant hepatic dysfunction is a contraindication, not a numerical dose-reduction category. Renal failure alters protein binding; total levels can mislead despite label PK data suggesting no routine renal adjustment. Adjust to clinical status and, when appropriate, unbound concentration rather than inventing a CrCl percentage table.

Hepatic disease/significant hepatic dysfunction; known POLG-related mitochondrial disease; suspected POLG-related disease under age two; known urea-cycle disorder; ingredient/valproate hypersensitivity. Valproate is contraindicated for migraine prevention during pregnancy or without effective contraception in a woman of childbearing potential; inclusion of that restriction in an epilepsy-only label does not approve its migraine use. For epilepsy/bipolar pregnancy use, restrictions are stringent but are not a universal formal pregnancy contraindication.

Labels warn of potentially fatal hepatic injury, often during the first six months, particularly in children under two and POLG-related disease; fetal malformations, decreased IQ and neurodevelopmental effects; and potentially fatal pancreatitis. These risks require selection, counseling and ongoing clinical/laboratory surveillance.

Common reports include nausea/vomiting, abdominal discomfort, somnolence, dizziness, tremor, alopecia and weight change. Thrombocytopenia/liver-enzyme abnormalities can be dose-related; serious cytopenias, endocrine/reproductive effects and encephalopathy are reported. IV use can cause infusion-site reactions. Overdose can cause profound sedation/coma, heart block, hypernatremia and death; obtain emergency care. In severe overdose the increased free fraction can make extracorporeal removal useful, requiring toxicology-directed assessment, not a home treatment.

Carbapenems can sharply lower concentrations and cause breakthrough seizures: monitor frequently and consider alternative antibiotic/antiseizure therapy when levels drop or control deteriorates. Enzyme-inducing antiseizure drugs, rifampin, estrogen-containing contraceptives and methotrexate can lower valproate exposure; monitor levels/clinical response when added or stopped and adjust appropriately.

Aspirin can increase free valproate; use caution. Felbamate can increase exposure. Valproate inhibits lamotrigine clearance and increases serious rash risk: use the lamotrigine label’s lower/slower regimen. Review phenytoin free levels, carbamazepine-epoxide, phenobarbital/primidone, ethosuximide, tricyclics, diazepam, zidovudine and warfarin/coagulation. Propofol requires dose reduction/close cardiorespiratory monitoring. Rufinamide/valproate starts require low-dose instructions from both labels. This is a focused list, not a complete interaction checker.

Topiramate can produce hyperammonemia/encephalopathy and hypothermia even when each medicine was previously tolerated; assess symptoms and ammonia, with clinician-directed cessation. Alcohol and other sedatives add CNS depression. Valproate’s noninducing profile does not remove the need for effective contraception or review of estrogen-related valproate clearance.

Avoid valproate in epilepsy/bipolar pregnancy or planned pregnancy unless other options fail or are unacceptable; in anyone with childbearing potential, alternatives must fail/be unacceptable and effective contraception is needed. Migraine prevention is contraindicated in pregnancy or without effective contraception. Counsel girls at puberty and revisit plans regularly. Folic acid is recommended before conception and during pregnancy, but protection against valproate-specific neural-tube/cognitive harm is unproved. If pregnancy occurs, urgently contact the prescriber; abrupt seizure-drug withdrawal can cause life-threatening status epilepticus. Offer the NAAED pregnancy registry. Male infertility/sperm abnormalities have been reported.

Valproate enters human milk at lower concentrations than maternal serum. Balance breastfeeding benefits and treatment needs with infant risk; monitor infant jaundice/liver symptoms and unusual bruising/bleeding. Data do not establish a milk-production effect. This differs from pregnancy risk and is not a blanket breastfeeding contraindication.

Complex-partial label dosing is adults and age ≥10; absence indications and younger-child risk need specialist interpretation rather than one universal age cutoff. Under two, fatal hepatotoxicity risk is especially high; known/suspected POLG restrictions apply. IV safety below two was not studied. Pediatric mania and migraine efficacy was not established in Depakote ER trials. Older adults require lower starts and slower titration with hydration/nutrition/sedation monitoring.

Liver disease/significant dysfunction is contraindicated. Reduced albumin and altered binding can make total concentrations appear acceptable while free exposure is high in liver disease, renal failure, older age or displacement interactions. Label renal-failure PK data do not call for a routine numerical reduction, but clinical/free-level interpretation is essential; do not infer a universal dialysis or CRRT replacement schedule.

Divalproex dissociates to valproate in the GI tract. Exact therapeutic mechanisms are not established; increased brain GABA is a proposed contributor to antiseizure activity. A shared active ion does not prove equal release profiles or identical product indications.

Valproate is extensively hepatically metabolized, principally by glucuronidation and mitochondrial beta-oxidation. Protein binding is concentration-dependent, so free fraction rises as total concentration rises; unbound kinetics are more linear than total-drug kinetics. Monotherapy terminal half-life is approximately 9–16 hours and changes with enzyme-inducing therapy. ER has lower bioavailability than equal DR daily doses, explaining the specific conversion rule. Renal/liver disease and displacement affect interpretation.

Before therapy, assess indication/formulation, pregnancy plans/contraception, liver disease, mitochondrial/UCD history, medications, liver tests and CBC/coagulation. Follow liver tests frequently, particularly during six months, and CBC/coagulation periodically; check before surgery and during pregnancy. Measure valproate/co-drug concentrations for response, toxicity, interactions or switches; consider free levels when binding is altered. Check ammonia for relevant mental-status/GI/hypothermia symptoms. Follow seizure/mood/migraine response, suicidality, weight, tremor, sedation and intake. Do not invent one fixed interval or use a level alone to exclude toxicity.

Take the exact prescribed product/schedule; never crush ER/DR, chew sprinkle beads or improvise route conversion. Do not double missed doses or abruptly stop seizure therapy. Seek urgent care for severe abdominal symptoms, jaundice, profound lethargy/confusion, rash/fever/facial swelling, bleeding or suicidal thoughts. Discuss reproductive risks and pregnancy promptly. Avoid unsafe driving until effects are known; review alcohol and all new medicines. Report tablet/bead residue in stool for clinical assessment of response/levels.

AbbVie Depakote DR 250 mg is peach-colored, marked NR (with or without the a logo); original logo bottle of 100 NDC 0074-6214-13. ER 500 mg is gray ovaloid, HC (logo or nonlogo); logo bottle of 100 NDC 0074-7126-13. Sprinkle 125 mg is white/blue, bottle of 100 NDC 0074-6114-13. Actavis valproic-acid 250-mg soft capsules are off-white marked VALPROIC 250, NDC 0591-4012-01. PAI solution bottle 473 mL is NDC 0121-0675-16. Sagent IV 500 mg/5 mL single-dose vial, ten per carton: NDC 25021-797-05.

Covered Depakote DR tablets: 125, 250, 500 mg; ER tablets: 250, 500 mg; DR sprinkle capsules: 125 mg. Valproic-acid soft capsule: 250 mg; oral solution as sodium salt: 250 mg/5 mL. IV sodium valproate: valproic-acid equivalent 100 mg/mL, 5-mL vial. These amounts express active equivalent, not interchangeable release kinetics or approved indications.

Depakote DR: below 30°C; ER: 25°C, excursions 15–30°C; Sprinkle: below 25°C. Actavis soft capsules: 15–30°C, tight/light-resistant container. PAI solution and Sagent unopened IV: 20–25°C. IV is preservative-free; discard unused vial contents. Compatible diluted IV preparations have labeled physical/chemical stability for at least 24 hours at 15–30°C, which does not override aseptic preparation/use requirements. Oral sprinkle-food mixtures must be consumed immediately.